| 1. |
- Bernhard, Juerg, et al.
(författare)
-
Clinical Benefit Response in Pancreatic Cancer Trials Revisited
- 2014
-
Ingår i: Oncology Research and Treatment. - : S. Karger AG. - 2296-5270 .- 2296-5262. ; 37:1-2, s. 42-48
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: Clinical benefit response (CBR), based on changes in pain, Karnofsky performance status, and weight, is an established palliative endpoint in trials for advanced gastrointestinal cancer. We investigated whether CBR is associated with survival, and whether CBR reflects a wide-enough range of domains to adequately capture patients' perception. Methods: CBR was prospectively evaluated in an international phase III chemotherapy trial in patients with advanced pancreatic cancer (n = 311) in parallel with patient-reported outcomes (PROs). Results: The median time to treatment failure was 3.4 months (range: 0-6). The majority of the CBRs (n = 39) were noted in patients who received chemotherapy for at least 5 months. Patients with CBR (n = 62) had longer survival than non-responders (n = 182) (hazard ratio = 0.69; 95% confidence interval: 0.51-0.94; p = 0.013). CBR was predicted with a sensitivity and specificity of 77-80% by various combinations of 3 mainly physical PROs. A comparison between the duration of CBR (n = 62, median = 8 months, range = 4-31) and clinically meaningful improvements in the PROs (n = 100-116; medians = 9-11 months, range = 4-24) showed similar intervals. Conclusion: CBR is associated with survival and mainly reflects physical domains. Within phase III chemotherapy trials for advanced gastrointestinal cancer, CBR can be replaced by a PRO evaluation, without losing substantial information but gaining complementary information.
|
|
| 2. |
|
|
| 3. |
- Gugliotta, L., et al.
(författare)
-
Treatment Of Essential Thrombocythaemia In Europe : An Observational Study Of 3649 High-Risk Patients In Exels
- 2015
-
Ingår i: Haematologica. - St Orsola Malpighi Hosp, Dept Hematol, L&A Seragnoli, Bologna, Italy. Univ Bari, Hematol Transplantat, Bari, Italy. Osped Maggiore della Carita, Novara, Italy. IRCCS Casa Sollievo Sofferenza, Div Ematol, San Giovanni Rotondo, FG, Italy. Arcispedale S Maria Nuova, Reggio Emilia, Italy. Hop St Louis, APHP, Ctr Invest Clin, Paris, France. Hosp del Mar IMIM, Dept Hematol, Barcelona, Spain. Johannes Wesling Med Ctr, Hematol & Oncol, Minden, Germany. Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England. Shire Pharmaceut, Global Biometr, Wayne, NJ USA. Shire Int GmbH, Res & Dev, Zug, Switzerland. Uppsala Univ, Dept Haematol, Uppsala, Sweden.. - 0390-6078 .- 1592-8721. ; 38, s. 216-216
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Mair, MJ, et al.
(författare)
-
Career and Professional Development for Young Oncologists
- 2023
-
Ingår i: Oncology research and treatment. - : S. Karger AG. - 2296-5262 .- 2296-5270. ; 46:3, s. 67-70
-
Tidskriftsartikel (refereegranskat)abstract
- Young oncologists around the globe face many challenges when it comes to their career and professional development. Aspects such as time management, work-life balance, career progression, and educational opportunities are only some of them. Professional societies have identified these challenges in this professional group and designed programs to tackle them specifically. The importance of this strategy cannot be overstated, as young oncologists, defined by most societies as oncologists under 40 years of age, compose almost 50% of the oncology workforce. On the other hand, recent surveys have shown that many young oncologists are considering alternative career paths due to burnout issues aggravated by the COVID-19 pandemic, on top of all other challenges. The virtual setting that has been forcedly introduced into our professional life has shortened distances between professionals and might have contributed to more accessible access to information and opportunities that some young oncologists could not profit from due to their traveling constraints. On the other hand, this virtual setting has shown us the asymmetries in opportunities for these professionals. Knowledgeable of all this, we summarize in this article some of the career and professional development offers available to all young oncologists, which we consider could help them deal with current and future challenges.
|
|
| 8. |
- Mauri, Davide, et al.
(författare)
-
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy : Time to Rethink Our Approach
- 2022
-
Ingår i: Oncology Research and Treatment. - : S. Karger. - 2296-5270 .- 2296-5262. ; 45:4, s. 216-220
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge.Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions.Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.
|
|
| 9. |
|
|
| 10. |
|
|
